Literature DB >> 34463938

Involvement of 4-hydroxy-2-nonenal in the pathogenesis of pulmonary fibrosis.

Edilburga Reyes-Jiménez1, Alma Aurora Ramírez-Hernández1, Jovito Cesar Santos-Álvarez1, Juan Manuel Velázquez-Enríquez1, Socorro Pina-Canseco2, Rafael Baltiérrez-Hoyos3, Verónica Rocío Vásquez-Garzón4.   

Abstract

Pulmonary fibrosis is a chronic progressive disease with high incidence, prevalence, and mortality rates worldwide. It is characterized by excessive accumulation of extracellular matrix in the lung parenchyma. The cellular and molecular mechanisms involved in its pathogenesis are complex, and some are still unknown. Several studies indicate that oxidative stress, characterized by overproduction of 4-hydroxy-2-nonenal (4-HNE), is an important player in pulmonary fibrosis. 4-HNE is a highly reactive compound derived from polyunsaturated fatty acids that can react with proteins, phospholipids, and nucleic acids. Thus, many of the altered cellular mechanisms that contribute to this disease can be explained by the participation of 4-HNE. Here, we summarize the current knowledge on the molecular states and signal transduction pathways that contribute to the pathogenesis of pulmonary fibrosis. Furthermore, we describe the participation of 4-HNE in various mechanisms involved in pulmonary fibrosis development, with a focus on the cell populations involved in the initiation, development, and maintenance of the fibrotic process, mainly alveolar cells, endothelial cells, macrophages, and inflammatory cells. Due to its characteristic activity as a second messenger, 4-HNE, in addition to being a consequence of oxidative stress, can support maintenance of the inflammatory and fibrotic process by spreading the effects of reactive oxygen species (ROS). Thus, regulation of 4-HNE levels could be a viable strategy to reduce its effects on the mechanisms involved in pulmonary fibrosis development.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  4-hydroxynonenal; Inflammation; Metabolism; Oxidative stress; Pulmonary fibrosis; Signal transduction

Mesh:

Substances:

Year:  2021        PMID: 34463938     DOI: 10.1007/s11010-021-04244-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  94 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 2.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Authors:  John Hutchinson; Andrew Fogarty; Richard Hubbard; Tricia McKeever
Journal:  Eur Respir J       Date:  2015-05-14       Impact factor: 16.671

3.  Viral Infection Increases the Risk of Idiopathic Pulmonary Fibrosis: A Meta-Analysis.

Authors:  Gaohong Sheng; Peng Chen; Yanqiu Wei; Huihui Yue; Jiaojiao Chu; Jianping Zhao; Yihua Wang; Wanguang Zhang; Hui-Lan Zhang
Journal:  Chest       Date:  2019-11-12       Impact factor: 9.410

4.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

5.  Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice.

Authors:  Jooeun Lee; Raghava Reddy; Lora Barsky; Jessica Scholes; Hui Chen; Wei Shi; Barbara Driscoll
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-10-24       Impact factor: 5.464

6.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

7.  Successful double-lung transplantation from a donor previously infected with SARS-CoV-2.

Authors:  Laurens J Ceulemans; Jan Van Slambrouck; Paul De Leyn; Herbert Decaluwé; Hans Van Veer; Lieven Depypere; Vincent Ceuterick; Stijn E Verleden; Arno Vanstapel; Stefanie Desmet; Piet Maes; Marc Van Ranst; Piet Lormans; Geert Meyfroidt; Arne P Neyrinck; Bart M Vanaudenaerde; Eric Van Wijngaerden; Saskia Bos; Laurent Godinas; Peter Carmeliet; Geert M Verleden; Dirk E Van Raemdonck; Robin Vos
Journal:  Lancet Respir Med       Date:  2020-12-01       Impact factor: 30.700

8.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

9.  Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century.

Authors:  John P Hutchinson; Tricia M McKeever; Andrew W Fogarty; Vidya Navaratnam; Richard B Hubbard
Journal:  Ann Am Thorac Soc       Date:  2014-10

10.  Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK.

Authors:  Helen Strongman; Imran Kausar; Toby M Maher
Journal:  Adv Ther       Date:  2018-04-11       Impact factor: 3.845

View more
  4 in total

1.  Links between Disease Severity, Bacterial Infections and Oxidative Stress in Cystic Fibrosis.

Authors:  Sabina Galiniak; Mateusz Mołoń; Marta Rachel
Journal:  Antioxidants (Basel)       Date:  2022-04-29

Review 2.  Hsp70 in Redox Homeostasis.

Authors:  Hong Zhang; Weibin Gong; Si Wu; Sarah Perrett
Journal:  Cells       Date:  2022-02-28       Impact factor: 6.600

3.  3'5-Dimaleamylbenzoic Acid Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.

Authors:  Karina González-García; Armando López-Martínez; Juan Manuel Velázquez-Enríquez; Cecilia Zertuche-Martínez; Gabriela Carrasco-Torres; Luis Manuel Sánchez-Navarro; Saúl Villa-Treviño; Rafael Baltiérrez-Hoyos; Verónica Rocío Vásquez-Garzón
Journal:  Int J Mol Sci       Date:  2022-07-19       Impact factor: 6.208

4.  3'UTR shortening of profibrotic genes and reversibility of fibrosis in patients with end-stage right ventricular failure.

Authors:  Rahul Neupane; Katarzyna A Cieslik; Keith Youker; Suresh Selvaraj Palaniyandi; Ashrith Guha; Rajarajan A Thandavarayan
Journal:  Clin Transl Med       Date:  2022-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.